The Key to the Semantic Web



By Johan Bostrom, IDG News Service

June 10, 2005 | The Semantic Web could be the key to unlocking scientific data that is sequestered by disparate applications and organizational limitations, and it could allow scientists to harness computation’s full power. That was the view of World Wide Web inventor Sir Tim Berners-Lee, in a spirited opening keynote address.

The Semantic Web “will give scientists and other users unexpected help and serendipitous added value from others’ data,” said Berners-Lee, who is director of the World Wide Web Consortium (W3C)
at MIT.

Sir Tim Berners-Lee

RALLY CRY: Berners-Lee
encouraged the life sciences to
pioneer the Semantic Web.
Photo by Fayfoto 

The Semantic Web seeks to make it easier for data on the Web to be shared and reused by people and applications. It is based on the W3C’s Resource Description Framework (RDF), which uses XML to integrate applications. Documents and information in databases on the Semantic Web have to be published in a machine-processable form, creating a kind of global database.

Life scientists in particular, Berners-Lee insisted, could find the Semantic Web a valuable tool, and in so doing, “provide leadership to lots of other fields” in implementing this next-generation Web technology. “I see a huge amount of energy from people in life sciences, getting excited by the Semantic Web and what it can do to solve the big-idea problems,” he said.

Berners-Lee has long envisioned an extension of the organic, unstructured Web. The W3C launched the first projects in the late 1990s, adding metadata to Web pages. Now, Berners-Lee hopes that life sciences will drive adoption of the Semantic Web, just as high-energy physics drove the early Web.

“Maybe we will meet a critical mass in a certain area,” he said. “The Web, for example, took off in high-energy physics. When we got six high-energy physics Web sites, then it got interesting for physicists to be onboard. Similarly, if we could get critical mass in life sciences, if we get a half-a-dozen or a dozen sets of ontologies [controlled vocabularies and hierarchical data structures], the core ones for drug discovery out there, then suddenly the Semantic Web within life sciences would have a critical mass. It’ll snowball much more rapidly, and it will be copied. Other areas will realize: Oh, it’s worth investing in this.”

Life sciences are particularly suitable for pioneering the Semantic Web, Berners-Lee said. For example, within drug discovery, many databases and information systems used by drug researchers are already in, or are ready to be transformed to, machine-readable formats.

Two such examples are the Biological Pathways Exchange, which is developing a standard data format for metabolic, signaling, and genetic pathway information, and the Universal Protein Resource (UniProt), joining information contained in catalogs of information on proteins.

“In many cases, like UniProt, the ontology exists, the modeling has already been done,” Berners-Lee said.

Advanced Web

BioDASH, a Semantic Web prototype of a drug development dashboard, associates diseases, drug progression stages, molecular biology, and pathway knowledge for users. The prototype was developed by representatives from the W3C, IBM, Oracle, the University of Colorado, and others. It includes a Semantic Web browser connecting information from public sources and chemical libraries with genes, proteins, and pathways.

Berners-Lee does not promise a quick return on investment for those formatting their data to suit the Semantic Web, and he admits that the concept is “quite difficult to explain.” However, he experienced the same problem trying to explain the World Wide Web 15 years ago: “‘Hypertext pages; big deal!’ people said. They couldn’t realize how they would be able to link to potentially anything and what that would mean.” He told the packed audience that if only 20 people “get it” and help promote the Semantic Web in their organizations, that would be a major advance.

When asked what he considered his most gratifying application of the Web over the past 15 years, Berners-Lee pointed to the amazing diversity of uses that people have found for the Web. He hoped the same could be said of the Semantic Web.

Asked when the Semantic Web will take off, Berners-Lee said: “You tell me. I spend all my energy just telling people what I would like to see happen. What I think will happen is much more dangerous.”

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .